No quarterly revenue total was found in Semnur Pharmaceuticals, Inc.'s SEC filings.
Semnur Pharmaceuticals, Inc. (SMNR) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-3.63M
+97.6% vs year-ago quarter
Operating cash flow
$-2.22M
-4.3% vs year-ago quarter
Free cash flow
—
EPS
$-0.02
+97.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
217.71M
-5.2% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SMNR (OTC), SMNRW (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Palo Alto, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1913577
- Former names
- Denali Capital Acquisition Corp. (until Sep 23, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$3.6M | -$4.2M | -$4.6M | -$6.2M | -$152.6M |
| Net income | -$3.6M | -$4.3M | -$4.6M | -$6.2M | -$152.6M |
| Diluted EPS | -$0.02 | -$0.02 | -$0.02 | -$0.03 | -$0.76 |
| Operating cash flow | -$2.2M | -$2.1M | -$2.7M | -$3.6M | -$2.1M |
| Total assets | $2.0M | $1.9M | $2.0M | $1.3M | $774,000 |
| Total liabilities | $35.3M | $31.6M | $27.3M | $22.1M | $15.4M |
| Stockholders' equity | -$33.3M | -$29.7M | -$25.3M | -$20.8M | -$14.6M |
| Cash and investments | $54,000 | $39,000 | $103,000 | $20,000 | $85,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Jul 7, 2026 | Jul 3, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 25, 2026 | Jun 25, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| ARS | Annual report to shareholders | Apr 30, 2026 | Dec 31, 2025 |
All 221 Semnur Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.